Every material Form 8-K Trevi Therapeutics, Inc. has filed with the SEC since April 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Trevi Therapeutics reported a third-quarter 2026 net loss of $21.5 million, or $0.13 per share, up from $11.8 million, or $0.08 per share, a year earlier, as research and development expenses rose to $19.1 million from $10.1 million. The company ended the quarter with $299.4 million in cash, cash equivalents and marketable securities and said this funds cash runway into 2030, which matters to shareholders because spending is rising and the filing shows no revenue line.
Net loss of $21.5 million for the quarter ended September 30, 2026, versus $11.8 million in the same period of 2025
Research and development expenses of $19.1 million, up from $10.1 million, driven by Phase 3 OCEAN-1 and OCEAN-2 and Phase 2b LAKE trials
Cash, cash equivalents and marketable securities of $299.4 million at September 30, 2026; the company expects cash runway into 2030
Positive FDA meeting in October 2026 on the non-IPF ILD program; Phase 2 dose-ranging trial expected to start in the first quarter of 2027
Trevi Therapeutics reported a second-quarter 2026 net loss of $17.8 million, or $0.11 per share, compared with a net loss of $12.3 million, or $0.09 per share, a year earlier. Research and development and general and administrative spending both rose, and the company ended the quarter with $318.9 million in cash, cash equivalents and marketable securities after an April 2026 stock offering, which it says extends its cash runway into 2030.
Net loss for Q2 2026 was $17.8 million, versus $12.3 million in Q2 2025; loss per share was $0.11 versus $0.09.
R&D expenses rose to $15.2 million from $9.4 million, mainly due to Phase 3 OCEAN-1, Phase 2b LAKE and Phase 3 OCEAN-2 trial costs.
G&A expenses rose to $5.4 million from $4.3 million, driven by stock-based compensation and personnel costs.
Cash, cash equivalents and marketable securities were $318.9 million at June 30, 2026; the April 2026 offering brought in net proceeds of about $162.3 million.
Trevi Therapeutics reported a first-quarter 2026 net loss of $13.2 million, up from $10.3 million a year earlier, as research and development and general and administrative expenses rose. The company said an April 2026 common stock offering, with net proceeds of about $162 million, extends its expected cash runway into 2030, and it reiterated plans to start Phase 3 trials in IPF-related chronic cough.
Net loss of $13.2 million for the quarter ended March 31, 2026, versus $10.3 million in the same period of 2025
R&D expenses rose to $9.9 million from $7.8 million; G&A expenses rose to $5.0 million from $3.7 million
Net proceeds of about $162 million from the underwritten common stock offering completed in April 2026
Cash, cash equivalents and marketable securities were $171.8 million at March 31, 2026; first Phase 3 trial expected to start in the second quarter of 2026
Trevi Therapeutics agreed to sell 11.6 million new common shares at $13.00 each, for about $150 million before fees, with the Company estimating net proceeds of about $141.1 million. The Company said it had about $171.8 million in cash and securities as of March 31, 2026, and that this cash plus the offering proceeds will fund operations through 2029, while the sale also adds new shares outstanding for existing holders.
Offering of 11.6 million shares at $13.00 per share, with underwriters at $12.22 per share; closing expected on or about April 20, 2026.
Estimated net proceeds of about $141.1 million, or about $162.4 million if the 1,740,000-share underwriter option is exercised in full.
Cash, cash equivalents and marketable securities of about $171.8 million as of March 31, 2026, preliminary and unreviewed by the auditor.
Company expects cash to fund operations through 2029; first Phase 3 trial topline results expected in the first half of 2028.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Trevi Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →